Becker's Healthcare October 23, 2024
Alexandra Murphy

The FDA approved Pfizer’s Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.

The approval is based on data from Pfizer’s Phase 3 MONeT trial, which evaluated the vaccine’s safety and efficacy in high-risk adults, according to an Oct. 22 news release from...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Why are women getting long COVID more than men?
How Climate-Driven Disasters Could Reshape Health Care Quality Measures
Journalists Discuss Health Care for Incarcerated Children and the Possibility of a Bird Flu Pandemic
What Is HKU5-CoV-2? Scientists Find Bat Virus Similar To COVID-19
Insights into the future of COVID-19 care

Share This Article